CRSP – crispr therapeutics ag - common shares (US:NASDAQ)

News

FDA Draft Guidance Puts CRISPR Therapeutics Rare Disease Outlook In Focus [Yahoo! Finance]
CRISPR Therapeutics touts zugo-cel CAR-T gains, eyes autoimmune expansion at Citi oncology summit [Yahoo! Finance]
Should You Buy Shares of CRISPR Therapeutics in February? [Yahoo! Finance]
CRISPR Therapeutics Q4: The Elite Time To Buy Is In 2027 [Seeking Alpha]
CRISPR Therapeutics (NASDAQ:CRSP) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com